Dyne reports cardiopulmonary benefits in Duchenne trial of z-rostudirsen in individuals amenable to skipping exon 51

As an early investor in Dyne Therapeutics, CureDuchenne is happy to share that new analyses out to 24 months showed improvement in heart and lung function with z-rostudirsen compared to declines observed in published Duchenne natural history data.   

Link to press release:  https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-new-positive-cardiopulmonary-results